ASTRAZENECA has rejected a £63bn takeover offer from US rival Pfizer, claiming it substantially undervalues the business.
The company turned down the bid from the Viagra maker hours after Pfizer stepped up its pursuit by making the increased offer and pledging the future of UK jobs and research.
At £50 a share, the offer represented a 7 per cent increase on a previous proposal in January.
However, an AstraZeneca spokesman said: “The financial and other terms described in the proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer.”
AstraZeneca has plants in London, Cheshire and Bristol.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here